StoxNATCO Pharma vs Concord Biotech: share price & financials comparison
NSE: NATCOPHARM vs CONCORDBIO · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
NATCO Pharma vs Concord Biotech at a glance
NATCO Pharma (NATCOPHARM) has a market capitalisation of ₹14,445 Cr, against ₹6,618 Cr for Concord Biotech (CONCORDBIO). Over the past year NATCO Pharma has returned -2.5%, compared with -12.9% for Concord Biotech. On valuation, NATCO Pharma trades at a lower P/E of 12.6 versus 23.4. Concord Biotech earns a higher return on equity (13.6% vs 12.4%). NATCO Pharma comes out ahead on size and valuation. Concord Biotech comes out ahead on profitability, growth and technicals. Across the scored metrics below, NATCO Pharma leads on 7 and Concord Biotech on 8. On StoxGud's 10-point checklist, NATCO Pharma scores 4/10 and Concord Biotech scores 6/10.
| Metric | NATCO Pharma | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹14,445 Cr | ₹6,618 Cr |
| Revenue (latest FY) | ₹4,078 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹1,418 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 12.6 | 23.4 |
| P/B | 1.57 | 3.19 |
| Dividend yield | 0.62% | 1.69% |
| Profitability | ||
| Return on equity | 12.4% | 13.6% |
| Net profit margin | 32.8% | 24.1% |
| Operating margin | 30.2% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | -44.7% | +25.1% |
| Net profit growth (YoY) | -57.0% | +11.1% |
| Revenue CAGR (multi-year) | +14.7% | +1.8% |
| Financial health | ||
| Debt to equity | 0.08 | 0.00 |
| Momentum | ||
| 1-month return | -0.4% | -7.0% |
| 1-year return | -2.5% | -12.9% |
| 3-year CAGR | +2.6% | +3.6% |
| 5-year CAGR | -1.5% | — |
| 10-year CAGR | +3.3% | — |
| Distance from 52W high | -33.1% | -20.3% |
| Technicals | ||
| RSI (14) | 62 | 45 |
| Price vs 200-day avg | -13.0% | -0.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | NATCO Pharma | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 4/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, NATCO Pharma or Concord Biotech?
NATCO Pharma has a market cap of ₹14,445 Cr and Concord Biotech has a market cap of ₹6,618 Cr as of 06 Nov 2026.
Which has a lower P/E, NATCO Pharma or Concord Biotech?
NATCO Pharma has the lower P/E: NATCO Pharma trades at 12.6 and Concord Biotech at 23.4.
Which gave better returns in the last year, NATCO Pharma or Concord Biotech?
NATCO Pharma did better: NATCO Pharma returned -2.5% and Concord Biotech returned -12.9% over one year.
Is NATCO Pharma or Concord Biotech a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist NATCO Pharma scores 4/10 and Concord Biotech scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.